Cyclosporine + Mycophenolate mofetil + Corticosteroids + Everolimus + Anti Thymocyte Globulin
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Renal Function and Chronic Allograft Vasculopathy
Conditions
Renal Function and Chronic Allograft Vasculopathy
Trial Timeline
Nov 1, 2009 → Dec 1, 2012
NCT ID
NCT01266148About Cyclosporine + Mycophenolate mofetil + Corticosteroids + Everolimus + Anti Thymocyte Globulin
Cyclosporine + Mycophenolate mofetil + Corticosteroids + Everolimus + Anti Thymocyte Globulin is a approved stage product being developed by Novartis for Renal Function and Chronic Allograft Vasculopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT01266148. Target conditions include Renal Function and Chronic Allograft Vasculopathy.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01266148 | Approved | Completed |
Competing Products
20 competing products in Renal Function and Chronic Allograft Vasculopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MBX 2109 + MBX 2109 + MBX 2109 + MBX 2109 | MBX Biosciences | Phase 1 | 28 |
| LY3473329 | Eli Lilly | Phase 1 | 33 |
| Tildacerfont/Placebo | Spruce Biosciences | Phase 2 | 44 |
| SPR001 | Spruce Biosciences | Phase 2 | 44 |
| SPR001 | Spruce Biosciences | Phase 2 | 44 |
| Tildacerfont/Placebo | Spruce Biosciences | Phase 2 | 44 |
| Tildacerfont | Spruce Biosciences | Phase 2 | 44 |
| Drotrecogin alfa activated (Xigris) | Eli Lilly | Phase 2 | 52 |
| LY3819469 | Eli Lilly | Phase 1 | 33 |
| Atezolizumab + Cabozantinib | Chugai Pharmaceutical | Phase 3 | 77 |
| DS-6000a + DS-6000a | Daiichi Sankyo | Phase 1 | 33 |
| DS-1093a | Daiichi Sankyo | Phase 1 | 33 |
| CS-3150 | Daiichi Sankyo | Phase 3 | 77 |
| AGS-16C3F | Astellas Pharma | Phase 1 | 33 |
| AGS-16M8F | Astellas Pharma | Phase 1 | 33 |
| CP-461 | Astellas Pharma | Phase 2 | 52 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| YM178 | Astellas Pharma | Phase 1 | 33 |
| intravenous immunoglobulins (IVIG) | Astellas Pharma | Phase 1 | 33 |
| bixalomer | Astellas Pharma | Pre-clinical | 23 |